NEWS

WIRES

OTHER

Advanced BioHealing to Present at Canaccord Adams Musculoskeletal Conference

Dr. Hart's presentation is scheduled for Tuesday, March 9, 2010, at 11:00 a.m. He will provide an overview of the Company including its product pipeline led by Dermagraft, ABH's bio-engineered skin substitute that repairs tissue damaged by disease and supports the body's natural healing process. Dermagraft is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers (DFUs) and is the focus of an ongoing pivotal trial in subjects with venous leg ulcers. The Company has also initiated plans to extend the use of Dermagraft into orthopedic soft tissue indications.

Since launching commercial operations in 2007, ABH has experienced double-digit revenue growth achieving more than $85 million in annual revenue for 2009 and surpassing 250 employees.

"We are pleased to have been invited to present at this year's Canaccord Adams Musculoskeletal Conference," said Dr. Hart. "The demonstrated effectiveness of Dermagraft in the treatment of DFUs suggests that this product should have clinical utility in the treatment of a variety of orthopedic indications related to soft tissue repair, such as rotator cuff tears. Exploring these possibilities is at the core of our efforts to expand the use of Dermagraft into new therapeutic areas."

About Advanced BioHealing, Inc.

Advanced BioHealing develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. A privately held company with more than 250 employees, Advanced BioHealing maintains its corporate office in Westport, CT, a 70,000 sq. ft. manufacturing facility in La Jolla, CA, and a research facility in Nashville, TN. To meet Advanced BioHealing's executives and learn more about the Company, please visit the Company's web site at www.ABH.com.

About Dermagraft

Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. It is FDA approved to treat diabetic foot ulcers and is the focus of an ongoing pivotal trial in subjects with venous leg ulcers (VLUs) to assess the product's safety and efficacy in the promotion of healing VLUs. More than 150,000 applications of Dermagraft have been administered in over 1,000 wound care centers and outpatient clinics nationwide. For videos of Dermagraft in action, case studies, research and more, visit www.Dermagraft.com.

Advanced BioHealing
Lindsey Hart, 773-697-3838
Cell: 206-335-0114
lhart@abh.com
or
Gregory FCA
Mike Lizun, 610-642-1435
Cell: 215-313-0441
Mike@GregoryFCA.com